Which is better, BIO or HALO?

On the Buffett-Fit framework, Halozyme Therapeutics, Inc. (HALO) currently grades higher than BIO — 79/100 (B grade) vs 43/100 (D). That said, "better" depends on which framework you trust — BIO wins on Joel Greenblatt; HALO wins on Warren Buffett, Benjamin Graham, Philip Fisher, Peter Lynch, Charlie Munger, and Terry Smith. The full pillar breakdown is on this page.

Should I buy BIO or HALO?

This page is an educational comparison, not investment advice. Both BIO and HALO are graded against the same Buffett 5-pillar framework (moat, earnings durability, management quality, financial health, valuation) plus six other documented investor frameworks. Read the side-by-side breakdown to see which one matches the criteria you care about most — and always do your own research before making any investment decision.

Is BIO better than HALO for value investing?

On the Buffett-style value-investing framework, HALO currently grades higher — 79/100 vs 43/100, a 36-point gap. The gap is driven by which pillars each stock passes; the table on this page shows moat, durability, management, financial health, and valuation side-by-side.

What's the difference between BIO and HALO on Warren Buffett's framework?

Both stocks are evaluated on the same five pillars: economic moat (durable competitive advantage), earnings durability (consistent profitability), management quality (capital allocation), financial health (conservative balance sheet), and valuation (margin of safety). BIO currently scores 43/100 (D grade); HALO scores 79/100 (B grade). The "Where each wins" section on this page breaks down which pillar each stock dominates.

Which has the stronger moat, BIO or HALO?

Moat strength is one of the five pillars in the Buffett-Fit score on this page. BIO and HALO are each scored on ROIC sustainability, gross-margin durability, and qualitative signals like brand strength, switching costs, network effects, and regulatory barriers. The pillar breakdown on this page shows the moat sub-score side-by-side so you can see which one has the more durable competitive advantage.

Which is more undervalued, BIO or HALO?

Valuation is one of the five Buffett-Fit pillars on this page. Both stocks are scored on owner-earnings yield, price-to-intrinsic-value vs the underlying compounding rate, and the margin of safety relative to a conservative DCF. The valuation sub-score in the table below tells you which one currently trades at a more attractive price relative to its underlying business quality.

Are BIO and HALO both Healthcare stocks?

Yes — both Bio-Rad Laboratories, Inc. (BIO) and Halozyme Therapeutics, Inc. (HALO) operate in the Healthcare sector. That makes this a direct sector-peer comparison, which is the apples-to-apples way to use the Buffett-Fit framework: the score weighs each stock against its sector's specific quality and valuation benchmarks (sector-relative bonus), so the cross-stock comparison isn't distorted by inter-sector base-rate differences.

Is this BIO vs HALO comparison investment advice?

No. This page is an educational pattern-match against documented public frameworks (Buffett, Graham, Fisher, Lynch, Greenblatt, Munger, Smith), not personalised investment advice. The scores reflect how closely each stock matches each framework's documented criteria — they are not buy/hold/sell recommendations. Always do your own research and consult a licensed financial adviser for personalised advice.

Stock comparison

Bio-Rad Laboratories

Halozyme Therapeutics

Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.

BIO

Market cap

$7.78B

Sector

Healthcare

HALO

Halozyme Therapeutics

Market cap

$8.1B

Sector

Healthcare

Overall winner

Halozyme Therapeutics HALO

Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.

Fit scores by strategy

Strategy	BIO	HALO	Winner
Warren Buffett	43D	79B	HALO
Benjamin Graham	48D	83A	HALO
Philip Fisher	30F	65B	HALO
Peter Lynch	10F	53D	HALO
Joel Greenblatt	42D	40D	BIO
Charlie Munger	34F	80C	HALO
Terry Smith	26F	84A	HALO

Side-by-side metrics

Metric	BIO	HALO
Market cap	$7.78B	$8.1B
P/E (TTM)	39.5x	24.0x
EV/EBIT	28.0x	10.2x
ROIC (TTM)	1.95%	23.65%
Gross margin	51.87%	81.24%
Net margin	6.52%	23.13%
Revenue CAGR 5y	-3.04%	33.23%
EPS CAGR 5y	-33.51%	-1.98%
Debt / Equity	0.2x	1.0x
Dividend yield	0.0%	0.0%

Where each one wins

The metrics with the biggest gap between the two - sorted so the most decisive edges read first.

BIO leads on

Debt / Equity0.2xvs 1.0x+79%

HALO leads on

Revenue CAGR 5y33.23%vs -3.04%+109%
EPS CAGR 5y-1.98%vs -33.51%+94%
ROIC (TTM)23.65%vs 1.95%+92%
Net margin23.13%vs 6.52%+72%

Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.

Bio-Rad Laboratories

Halozyme Therapeutics

Fit scores by strategy

Side-by-side metrics

Where each one wins

More like BIO

More like HALO

Related on invest-like

Key terms in this analysis